SELNET Clinical practice guidelines for bone sarcoma.

[1]  J. Blay,et al.  Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab , 2021, BMC Cancer.

[2]  D. Vanel,et al.  High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series , 2020, Cells.

[3]  E. Staals,et al.  Rare Primary Malignant Bone Sarcomas , 2020, Cancers.

[4]  H. Gelderblom,et al.  Current concepts in the treatment of giant cell tumour of bone. , 2020, Current opinion in oncology.

[5]  U. Dirksen,et al.  Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). , 2020, Journal of Clinical Oncology.

[6]  H. Gelderblom,et al.  Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). , 2020 .

[7]  L. Spector,et al.  Prognostic Factors for Development of Subsequent Metastases in Localized Osteosarcoma: A Systematic Review and Identification of Literature Gaps , 2020, Sarcoma.

[8]  P. Gikas,et al.  The sensitivity, specificity, and diagnostic accuracy of whole-bone MRI for identifying skip metastases in appendicular osteosarcoma and Ewing sarcoma , 2020, Skeletal Radiology.

[9]  P. Rose.  What's New in Musculoskeletal Tumor Surgery. , 2019, The Journal of bone and joint surgery. American volume.

[10]  J. Blay,et al.  Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. , 2019, The Lancet. Oncology.

[11]  S. Millis,et al.  Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma , 2019, Modern Pathology.

[12]  J. Blay,et al.  Surgery in reference centers improves survival of sarcoma patients: a nationwide study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  S. Ferrari,et al.  Bone marrow biopsy in the initial staging of Ewing sarcoma: Experience from a single institution , 2019, Pediatric blood & cancer.

[14]  K. S. Hall,et al.  Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. , 2019, Journal of Clinical Oncology.

[15]  J. Blay,et al.  Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. , 2019, The Lancet. Oncology.

[16]  S. Sleijfer,et al.  Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018 .

[17]  J. Blay,et al.  High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Campanacci,et al.  Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  J. Whelan,et al.  Osteosarcoma, Chondrosarcoma, and Chordoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Antonescu,et al.  BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas , 2017, The American journal of surgical pathology.

[21]  S. Bielack,et al.  EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma , 2018, Tumori.

[22]  L. Tang,et al.  Efficacy and safety of stereotactic radiosurgery for pulmonary metastases from osteosarcoma: Experience in 73 patients , 2017, Scientific Reports.

[23]  J. Blay,et al.  Improved survival using specialized multidisciplinary board in sarcoma patients. , 2017 .

[24]  F. Moreno,et al.  Childhood osteosarcoma: Incidence and survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000–2013 , 2017, Pediatric blood & cancer.

[25]  H. Peng,et al.  Is intralesional resection suitable for central grade 1 chondrosarcoma: A systematic review and updated meta-analysis. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[26]  C. Antonescu,et al.  Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases , 2017, The American journal of surgical pathology.

[27]  J. Blay,et al.  Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). , 2017, European Journal of Cancer.

[28]  J. Blay,et al.  Giant cell tumour of bone in the denosumab era. , 2017, European journal of cancer.

[29]  P. A. Gardner,et al.  Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Katherine E Henson,et al.  Cardiac Mortality Among 200 000 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age , 2016, Circulation.

[31]  K. S. Hall,et al.  Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial , 2016, The Lancet. Oncology.

[32]  T. Dipetrillo,et al.  Incidence, Treatment, and Survival Patterns for Sacral Chordoma in the United States, 1974–2011 , 2016, Front. Oncol..

[33]  A. Pappo,et al.  Comparison of 18F‐FDG‐PET‐CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma , 2016, Pediatric blood & cancer.

[34]  A. Liede,et al.  Population-based study of giant cell tumor of bone in Sweden (1983-2011). , 2016, Cancer epidemiology.

[35]  D. de Ruysscher,et al.  Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers. , 2016, International journal of radiation oncology, biology, physics.

[36]  S. Ferrari,et al.  Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone , 2016, BMC Cancer.

[37]  M. Díaz-Almirón,et al.  Enchondroma versus Chondrosarcoma in Long Bones of Appendicular Skeleton: Clinical and Radiological Criteria—A Follow-Up , 2016, Journal of oncology.

[38]  R. Grimer,et al.  The prognostic and therapeutic factors which influence the oncological outcome of parosteal osteosarcoma. , 2015, The bone & joint journal.

[39]  U. Dirksen,et al.  Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Blay,et al.  Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)† , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  F. Bray,et al.  Bone cancer incidence by morphological subtype: a global assessment , 2015, Cancer Causes & Control.

[42]  D. Biau,et al.  Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. , 2015, European journal of cancer.

[43]  S. Stacchiotti,et al.  Building a global consensus approach to chordoma: a position paper from the medical and patient community. , 2015, The Lancet. Oncology.

[44]  K. S. Hall,et al.  EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  A. Berner,et al.  Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma , 2014, Acta oncologica.

[46]  P. Casali,et al.  Sorafenib and everolimus combination in non-resectable high-grade osteosarcoma progressing after standard treatment: a non-randomized phase II clinical trial from the Italian Sarcoma Group. Abstract , 2022 .

[47]  Steven S. Wong,et al.  Regional variation and challenges in estimating the incidence of giant cell tumor of bone. , 2014, The Journal of bone and joint surgery. American volume.

[48]  B. Yeap,et al.  Long‐term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas , 2014, Journal of surgical oncology.

[49]  M. Stratton,et al.  Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone , 2013, Nature Genetics.

[50]  F. Bertucci,et al.  Advanced chondrosarcomas: role of chemotherapy and survival. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  L. Mariani,et al.  Phase II study on lapatinib in advanced EGFR-positive chordoma. , 2013 .

[52]  W. Mendenhall,et al.  Radiotherapy in the Management of Giant Cell Tumor of Bone , 2010, American journal of clinical oncology.

[53]  C. Stiller,et al.  Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. , 2013, European journal of cancer.

[54]  P. Dileo,et al.  Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment? , 2014, BMC Cancer.

[55]  W. Tap,et al.  Long‐term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high‐grade, operable osteosarcoma , 2012, Cancer.

[56]  J. Healey,et al.  Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  A. McTiernan,et al.  Incidence and survival of malignant bone sarcomas in England 1979–2007 , 2012, International journal of cancer.

[58]  Gerald Antoch,et al.  Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma , 2012, The Journal of Nuclear Medicine.

[59]  R. Stupp,et al.  Phase II study of imatinib in advanced chordoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Wathen,et al.  Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. , 2012, The oncologist.

[61]  U. Dirksen,et al.  Risk of recurrence and survival after relapse in patients with Ewing sarcoma , 2011, Pediatric blood & cancer.

[62]  R. Grimer,et al.  The 'other' bone sarcomas: prognostic factors and outcomes of spindle cell sarcomas of bone. , 2011, The Journal of bone and joint surgery. British volume.

[63]  W. Winkelmann,et al.  The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  S. Ferrari,et al.  Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  D. Vanel,et al.  Periosteal osteosarcoma , 2011, Cancer.

[66]  U. Dirksen,et al.  Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  T. Triche,et al.  Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  U. Dirksen,et al.  The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES) , 2010, Cancer.

[69]  A. Llombart‐Bosch,et al.  Molecular Diagnosis of Ewing Sarcoma Family of Tumors: A Comparative Analysis of 560 Cases With FISH and RT-PCR , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[70]  R. Scholten,et al.  Prognostic factors in localized extremity osteosarcoma: a systematic review. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[71]  L. Koniaris,et al.  Ewing sarcoma demonstrates racial disparities in incidence‐related and sex‐related differences in outcome , 2009, Cancer.

[72]  B. Massimo,et al.  Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high‐risk osteosarcoma patients , 2009 .

[73]  Lisa Mirabello,et al.  International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons , 2009, International journal of cancer.

[74]  D. Vanel,et al.  Response to high‐dose ifosfamide in patients with advanced/recurrent Ewing sarcoma , 2009, Pediatric blood & cancer.

[75]  Saskia Le Cessie,et al.  Assessment of Interobserver Variability and Histologic Parameters to Improve Reliability in Classification and Grading of Central Cartilaginous Tumors , 2009, The American journal of surgical pathology.

[76]  W. Winkelmann,et al.  Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  J. Eary,et al.  Imaging guidelines for children with Ewing sarcoma and osteosarcoma: A report from the Children's Oncology Group Bone Tumor Committee , 2008, Pediatric blood & cancer.

[78]  S. Bielack,et al.  Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults , 2008, Cancer.

[79]  P. Leavey,et al.  Ewing sarcoma: prognostic criteria, outcomes and future treatment , 2008, Expert review of anticancer therapy.

[80]  N. Willich,et al.  Whole Lung Irradiation in Patients with Exclusively Pulmonary Metastases of Ewing Tumors , 2008, Strahlentherapie und Onkologie.

[81]  H. Gelderblom,et al.  The clinical approach towards chondrosarcoma. , 2008, The oncologist.

[82]  Paul A Meyers,et al.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  Thomas Völker,et al.  Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  F. Sim,et al.  Surgical Management of Conventional Grade I Chondrosarcoma of Long Bones , 2007, Clinical orthopaedics and related research.

[85]  D. Biau,et al.  Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. , 2007, European journal of cancer.

[86]  Michael Scholz,et al.  Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. , 2007, International journal of radiation oncology, biology, physics.

[87]  M. van Glabbeke,et al.  Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. , 2007, Journal of the National Cancer Institute.

[88]  T. Peabody,et al.  Staging of Primary Malignancies of Bone , 2006, CA: a cancer journal for clinicians.

[89]  S. Bielack,et al.  Current strategies of chemotherapy in osteosarcoma , 2006, International Orthopaedics.

[90]  S. Henderson,et al.  Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas , 2006, The Journal of pathology.

[91]  S. Bielack,et al.  Periosteal osteosarcoma--a European review of outcome. , 2005, European journal of cancer.

[92]  S. Ferrari,et al.  Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  M. Nooij,et al.  Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. , 2005, European journal of cancer.

[94]  J. Habrand,et al.  Radiotherapeutic Factors in the Management of Cervical-basal Chordomas and Chondrosarcomas , 2004, Neurosurgery.

[95]  F. Sim,et al.  Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. , 2004, The Journal of bone and joint surgery. American volume.

[96]  T. Bauer,et al.  Recommendations for the reporting of bone tumors. Association of Directors of Anatomic and Surgical Pathology. , 2004, Human pathology.

[97]  S. Bielack,et al.  Delaying surgery with chemotherapy for osteosarcoma of the extremities , 2004, Expert opinion on pharmacotherapy.

[98]  P. Houghton,et al.  Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors , 2004, Clinical Cancer Research.

[99]  E. Pignotti,et al.  Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. , 2004, European journal of cancer.

[100]  M. Link,et al.  Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  S. Donaldson,et al.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.

[102]  S. Ferrari,et al.  Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  W. Winkelmann,et al.  Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. , 2003, International journal of radiation oncology, biology, physics.

[104]  S. Ferrari,et al.  High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  R. Grimer,et al.  Risk factors for survival and local control in chondrosarcoma of bone. , 2002, The Journal of bone and joint surgery. British volume.

[107]  D. Vanel,et al.  Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[108]  M. Bernstein,et al.  Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  A. Craft,et al.  Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  S. Ferrari,et al.  Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  M. van Glabbeke,et al.  Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  H. Avet-Loiseau,et al.  Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. , 1997, European journal of cancer.

[113]  P. Picci,et al.  Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  H. Kovar,et al.  Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data. , 1994, British Journal of Cancer.

[115]  P. Sorensen,et al.  A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS–family transcription factor, ERG , 1994, Nature Genetics.

[116]  E. Gehan,et al.  Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  H. Mankin,et al.  The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. , 1982, The Journal of bone and joint surgery. American volume.

[118]  W. Enneking,et al.  A System for the Surgical Staging of Musculoskeletal Sarcoma , 1980, Clinical orthopaedics and related research.